mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia

This publication has 60 references indexed in Scilit:

• Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082
  Pharmacological Reports, 2013
• Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
  CNS & Neurological Disorders - Drug Targets, 2011
• Metabotropic Glutamate Receptor II in the Brains of Parkinsonian Patients
  Journal of Neuropathology & Experimental Neurology, 2009
• Metabotropic Glutamate 5 Receptor Blockade Alleviates Akinesia by Normalizing Activity of Selective Basal-Ganglia Structures in Parkinsonian Rats
  Journal of Neuroscience, 2003
• Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Striatopallidal Synapse
  The Journal of Neuroscience, 2003
• Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment
  Brain, 2002
• Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease
  Pharmacology Biochemistry and Behavior, 2002
• Changes in metabotropic glutamate receptor 1-8 gene expression in the rodent basal ganglia motor loop following lesion of the nigrostriatal tract
  Neuropharmacology, 2002
• The group II metabotropic glutamate receptor agonist, DCG‐IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine‐treated rat
  British Journal of Pharmacology, 2000
• The metabotropic glutamate receptor (mGluRlα) is concentrated at perisynaptic membrane of neuronal subpopulations as detected by immunogold reaction
  Neuron, 1993